Given the close relationship between NF2 mutations and YAP activity, which leads to tumor growth [378], a clinical study explored the efficacy of VT3989 in individuals with advanced solid tumors with a high prevalence of malignant mesothelioma and other tumors with NF2 mutations, showing good tolerance and sustained anti-tumor responses (NCT04665206) [379]. Here, NF2 is linked to malignant mesothelioma.